Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
People have a theory on that other board that Shorts have new rules starting April 22nd so the stock price could rise tomorrow as less shorting will be possible. Any confirmation?
Staff Statement on Fully Paid Lending
Division of Trading and Markets Staff
April 16, 2021
[1] On October 22, 2020, Commission staff issued a no-action letter regarding the broker-dealer customer protection rule, Exchange Act Rule 15c3-3, in relation to certain fully-paid lending programs operated by some broker-dealers.[2] Rule 15c3-3(b)(3) requires broker-dealers entering into agreements with their customers who lend the broker-dealers fully-paid or excess margin securities to provide the securities lenders with collateral that fully secures the loans.[3] Staff’s letter stated that the staff would not recommend enforcement action to the Commission regarding these programs for six months from issuance of the letter, or until April 22, 2021, to give firms time to come into compliance with the Rule.[4]
https://www.sec.gov/news/public-statement/staff-fully-paid-lending
Please point out in the trial where LL "failed" with its severe patients.
Study done not for very severe and critical patients for a reason , company don’t think these are a best candidates for Lenzilumab ..
If the feeling will change they will do another study
Don- what say you about those limitations?
82% reduction in 14 day mortality in critical patients.
Remember, media irks only work when they’re given.
Leronlimab administered day 0 and day 7.
If this would be real, shorts would have covered a long time ago. Just 2 days to cover 35 mio shares? Who will believe this- impossible. I think this is fake news.
DonDonDonDon et al., any updates on the status of the possible EUA application?
Don- I figured you would dance around that question as always
Lenzulumab is a good drug but it has limitations as to who it can treat
Don- nice try the trials were not even close to being weighted the same in regards to severe to critical patients try again
Yet y'all we're saying GILD was going to buyout HGEN... Clearly, that ain't happening.
Don- why is it that the FDA want approve us under there pandemic guidelines that we clearly meet I would really like an answer to that question?
there is only one drug that has proven effective for S2C and that is Leronlimab period.
No matter what topic Dr Janet Woodcock posts about on her Twitter, the responses to her posts will be 95% about leronlimab. A lot of the posts are extremely rude. Hysterical that people think that harassing her will make her become pro-leronlimab. I used to think that leronlimab getting great data would lead to an EUA. But now I am starting to believe that an EUA is impossible no matter what how good the data.
https://twitter.com/DrWoodcockFDA?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
I love how CYDY investors simultaneously believe that all forces are conspiring against leronlimab yet also believe that the rules don't apply to them and exceptions are going to be made for leronlimab's approval.
Philippines is important right now because they have the opportunity to look at the data from LL directly for their own patients.
So we are to suggest that a potential EUA denial in the near future precludes the trials to come from garnering EUA or even full approval? This is barely coherent let alone remotely logical.
In the history of pharmacology, what drug was denied an EUA in the US and then made real revenue in a poor country? Can you name one example?
“... because getting an EUA in the US is the only road to real revenue.”
I am patiently waiting for this statement to be proven as false as I know it to be.
people here will look forward for the data from Philippines
Lero > Lenz. Measured by lives saved. Measured by the market in $$$. It’s all right there for all to see.
They also say what that something is: calm the cytokine storm. "Anecdotes don't get you off ecmo".
See, if they have 29 patients, that is a dataset for the doctors to do a suitable scientific study
It is pretty obvious that Dr Bream reads the message boards. In fact, there has been a few times when he was criticizing the company that he used the exact words I had previously used in my criticisms. Don't worry Dr Bream, I'll allow it. I take it as a compliment.
It seems that every time the Nasdaq is down that HGEN is down 5 times as much. Could that be solely from index funds selling? HGEN does have a low float so it would have a disproportionate effect.
CYDY = Jake Paul
I also believe in the “There’s room for more than 1 therapy“ approach.
Username checks out
the FDA does not place the same value on saving lives , sad as it is they just dont
Official market "Open," and market "Close" are the only official stats that matter, not a "high price intra-day." Thanks :)
No NP, No Leronlimab! No present CYDY
Nader gets his 3.
I am very curious about BRAZIL and BOLSONARO, but i have the strong feeling that he is still informed about LERONLIMAB!!!!!!!!!!!!!
As for the Philippines situation, I see that as a hail Mary by NP.
Liked “A post on Stocktwits... Best idea ever.... Lol
I have been pondering for hours about writing a Hollywood Thriller in which
BP with the help of high federal officials plot to take down a small
biotech that owns the secret sauce to save the universe . This high flier
scandal, full of suspense, greed and crimes within a background of
wide-scale manslaughter, would expose corruption and villains at the
highest levels of office. The movie title would be : “ The CYTODYN FILES “
and would cast Hollywood’s best actors/actresses.”
I did not ask. I only asked him to clarify if we could charge for CSP or not and referenced the FDA Bulletin. He confirmed we could charge for CSP
I like that HGEN is saying nothing. It makes us look good to the FDA. Even our low stock price makes us look good to the FDA. HGEN is not a greasy pump and dump. Durrant and Chappell have done things the right way. The FDA will appreciate that.
what does document say and go with that.
Compassionate use is not a means to commercialization, which means SELL IT.
82% REDUCTION IN MORTALITY among the entire critical arm of the trial